五种申克孢子丝菌的体外抗真菌药敏试验
In vitro antifungal susceptibilities of five species of sporothrix.
作者信息
Marimon Rita, Serena Carolina, Gené Josepa, Cano Josep, Guarro Josep
机构信息
Unitat de Microbiologia, Facultat de Medicina i Ciències de la Salut, Universitat Rovira i Virgili, Carrer Sant Llorenç, 21.43201 Reus, Spain.
出版信息
Antimicrob Agents Chemother. 2008 Feb;52(2):732-4. doi: 10.1128/AAC.01012-07. Epub 2007 Nov 26.
Abstract
Ninety-two isolates belonging to five species of the Sporothrix schenckii complex were tested in vitro against 12 antifungal agents, using a reference microdilution method. There were significant differences among the species; Sporothrix brasiliensis was the species that showed the best response to antifungals, and S. mexicana had the worst response. In general, terbinafine was the most active drug, followed by ketoconazole and posaconazole.
摘要
采用参考微量稀释法，对属于申克孢子丝菌复合体5个种的92株分离株进行了12种抗真菌药物的体外测试。各菌种之间存在显著差异；巴西孢子丝菌是对抗真菌药物反应最佳的菌种，而墨西哥孢子丝菌反应最差。总体而言，特比萘芬是活性最强的药物，其次是酮康唑和泊沙康唑。
相似文献
1
In vitro antifungal susceptibilities of five species of sporothrix.
Antimicrob Agents Chemother. 2008 Feb;52(2):732-4. doi: 10.1128/AAC.01012-07. Epub 2007 Nov 26.
2
Canine sporotrichosis: polyphasic taxonomy and antifungal susceptibility profiles of Sporothrix species in an endemic area in Brazil.
Braz J Microbiol. 2021 Mar;52(1):135-143. doi: 10.1007/s42770-020-00328-8. Epub 2020 Jul 2.
3
Refractory sporotrichosis due to Sporothrix brasiliensis in humans appears to be unrelated to in vivo resistance.
Med Mycol. 2017 Jul 1;55(5):507-517. doi: 10.1093/mmy/myw103.
4
Antifungal susceptibilities and identification of species of the Sporothrix schenckii complex isolated in Brazil.
Med Mycol. 2014 Jan;52(1):56-64. doi: 10.3109/13693786.2013.818726.
5
Sporothrix schenckii complex in Iran: Molecular identification and antifungal susceptibility.
Med Mycol. 2016 Aug 1;54(6):593-9. doi: 10.1093/mmy/myw006. Epub 2016 Mar 1.
6
Genetic diversity and antifungal susceptibility profiles in causative agents of sporotrichosis.
BMC Infect Dis. 2014 Apr 23;14:219. doi: 10.1186/1471-2334-14-219.
7
Multicenter, International Study of MIC/MEC Distributions for Definition of Epidemiological Cutoff Values for Sporothrix Species Identified by Molecular Methods.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01057-17. Print 2017 Oct.
8
Antifungal susceptibilities of Sporothrix albicans, S. brasiliensis, and S. luriei of the S. schenckii complex identified in Brazil.
J Clin Microbiol. 2011 Aug;49(8):3047-9. doi: 10.1128/JCM.00255-11. Epub 2011 Jun 8.
9
Sporotrichosis caused by Sporothrix brasiliensis in Argentina: Case report, molecular identification and in vitro susceptibility pattern to antifungal drugs.
J Mycol Med. 2020 Apr;30(1):100908. doi: 10.1016/j.mycmed.2019.100908. Epub 2019 Oct 15.
10
Susceptibility of Sporothrix brasiliensis isolates to amphotericin B, azoles, and terbinafine.
Med Mycol. 2015 Feb 1;53(2):178-88. doi: 10.1093/mmy/myu056. Epub 2014 Nov 13.
引用本文的文献
1
Sporothrix is neglected among the neglected.
PLoS Pathog. 2025 Mar 6;21(3):e1012898. doi: 10.1371/journal.ppat.1012898. eCollection 2025 Mar.
2
Therapeutic alternatives for sporotrichosis induced by wild-type and non-wild-type Sporothrix schenckii through in vitro and in vivo assessment of enilconazole, isavuconazole, posaconazole, and terbinafine.
Sci Rep. 2025 Jan 25;15(1):3230. doi: 10.1038/s41598-025-87711-3.
3
Clinical Manifestations, Antifungal Drug Susceptibility, and Treatment Outcomes for Emerging Zoonotic Cutaneous Sporotrichosis, Thailand.
Emerg Infect Dis. 2024 Dec;30(12):2583-2592. doi: 10.3201/eid3012.240467.
4
Novel Insights into Sporotrichosis and Diabetes.
J Fungi (Basel). 2024 Jul 29;10(8):527. doi: 10.3390/jof10080527.
5
Milteforan, a promising veterinary commercial product against feline sporotrichosis.
Microbiol Spectr. 2024 Oct 3;12(10):e0047424. doi: 10.1128/spectrum.00474-24. Epub 2024 Aug 28.
6
Milteforan, a promising veterinary commercial product against feline sporotrichosis.
bioRxiv. 2024 Feb 15:2024.02.14.580352. doi: 10.1101/2024.02.14.580352.
7
A Randomized Clinical Trial Comparing Itraconazole and a Combination Therapy with Itraconazole and Potassium Iodide for the Treatment of Feline Sporotrichosis.
J Fungi (Basel). 2024 Jan 26;10(2):101. doi: 10.3390/jof10020101.
8
Phenotypic and Genotypic Characterization and Antifungal Susceptibility of Isolated from a Feline Sporotrichosis Outbreak in Bangkok, Thailand.
J Fungi (Basel). 2023 May 18;9(5):590. doi: 10.3390/jof9050590.
9
Current Progress in Basic Aspects.
J Fungi (Basel). 2023 Apr 29;9(5):533. doi: 10.3390/jof9050533.
10
Severe Sporotrichosis Caused by Sporothrix brasiliensis: Antifungal Susceptibility and Clinical Outcomes.
J Fungi (Basel). 2022 Dec 28;9(1):49. doi: 10.3390/jof9010049.
本文引用的文献
1
Sporothrix brasiliensis, S. globosa, and S. mexicana, three new Sporothrix species of clinical interest.
J Clin Microbiol. 2007 Oct;45(10):3198-206. doi: 10.1128/JCM.00808-07. Epub 2007 Aug 8.
2
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Antimicrob Agents Chemother. 2006 Dec;50(12):4211-3. doi: 10.1128/AAC.00981-06. Epub 2006 Oct 2.
3
Molecular phylogeny of Sporothrix schenckii.
J Clin Microbiol. 2006 Sep;44(9):3251-6. doi: 10.1128/JCM.00081-06.
4
Molecular phylogeny of the Pseudallescheria boydii species complex: proposal of two new species.
J Clin Microbiol. 2005 Oct;43(10):4930-42. doi: 10.1128/JCM.43.10.4930-4942.2005.
5
In vitro antifungal susceptibilities of Sporothrix schenckii in two growth phases.
Antimicrob Agents Chemother. 2005 Sep;49(9):3952-4. doi: 10.1128/AAC.49.9.3952-3954.2005.
6
Sporotrichosis.
Int J Dermatol. 2001 Dec;40(12):737-42. doi: 10.1046/j.1365-4362.2001.01295.x.
7
Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B.
Med Mycol. 2001 Aug;39(4):369-71. doi: 10.1080/mmy.39.4.369.371.
8
Gene genealogies, cryptic species, and molecular evolution in the human pathogen Coccidioides immitis and relatives (Ascomycota, Onygenales).
Mol Biol Evol. 2001 Jul;18(7):1246-58. doi: 10.1093/oxfordjournals.molbev.a003910.
9
Activity of terbinafine against serious fungal pathogens.
Mycoses. 1999;42 Suppl 2:115-9.
10
Terbinafine: broad new spectrum of indications in several subcutaneous and systemic and parasitic diseases.
Mycoses. 1999;42 Suppl 2:111-4.
Zotero 插件